Rep. Doris Matsui (D-CA) today introduced an AHA-supported bill that would make changes to the 340B drug savings program, including overturning last year’s significant Medicare payment reduction for many hospitals in the program and adding program integrity requirements for drug manufacturers participating in the program. “Hospitals and clinics doing life-saving work rely on the 340B program to help them provide inclusive and affordable care in their communities,” Matsui said. “This legislation makes clear the importance of preserving the program so safety net providers can continue to serve low-income and vulnerable patients, while expanding it to help address the opioid crisis.” Specifically, the Stretching Entity Resources for Vulnerable (SERV) Communities Act would overturn the nearly 30% Medicare payment cut that went into effect Jan. 1 for certain hospitals for outpatient drugs purchased under the 340B program. Among other provisions, the bill would require implementation of the long delayed 340B ceiling price calculation methodology and application of civil monetary penalties for manufacturers’ violations of the ceiling price.

Related News Articles

Perspective
Public
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…
Headline
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and…
Blog
Public
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing…
Headline
Update: The Senate passed the measure by a vote of 71-29.The Senate Jan. 30 is expected to pass a government funding plan ahead of a midnight deadline. A…
Headline
The AHA Jan. 28 released its 2026 Advocacy Agenda, containing the association’s key priorities for Congress, the administration, regulatory agencies and courts…